<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01290913</url>
  </required_header>
  <id_info>
    <org_study_id>CHB10090470</org_study_id>
    <secondary_id>Xolair and Peanut Allergy</secondary_id>
    <nct_id>NCT01290913</nct_id>
  </id_info>
  <brief_title>Xolair Enhances Oral Desensitization in Peanut Allergic Patients</brief_title>
  <official_title>Xolair Enhances Oral Desensitization in Peanut Allergic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lynda Schneider</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children’s Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot feasibility study, using Xolair pretreatment for oral peanut desensitization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We hypothesize that pretreatment with anti-IgE mAb will greatly reduce the side effects and
      allergic reactions that occur during oral desensitization to peanut and will enhance the
      development of oral tolerance in patients with severe peanut allergy.

      We will follow the patients for 5 years following study completion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 500 mg Peanut Flour (Cumulative Dose, 1,000 mg)</measure>
    <time_frame>First day of desensitization</time_frame>
    <description>To tolerate refers to the ability of the patient to ingest the challenge dose of 500 mg peanut flour (1000 mg cumulatively) with either no or mild symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 4,000 mg of Peanut Flour.</measure>
    <time_frame>after 7-8 wks of desensitization</time_frame>
    <description>To tolerate refers to the ability of the patient to ingest the final challenge of 4000mg peanut flour, with either no or mild symptoms.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>omalizumab, oral desensitization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive omalizumab along with oral peanut desensitization.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>Omalizumab is an antibody that helps decrease allergic responses in the body</description>
    <arm_group_label>omalizumab, oral desensitization</arm_group_label>
    <other_name>Xolair</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with severe peanut allergy, between the ages of 7-25 years, having a history
             of significant clinical symptoms within 1 hr of peanut ingestion.

          2. Total IgE &gt;50 kU/L but &lt;2,0000 kU/L.

          3. Sensitivity to peanut will be documented by a positive skin prick test result and RAST
             test to peanut, with 20 kU/L as a lower limit for eligibility.

          4. Patients must also fail a double blind food challenge with peanut at a dose of 100 mg
             or less (after a cumulative dose of 186 mg), with minimal or no reactions to the
             placebo challenge.

          5. All female subjects of childbearing potential will be required to provide a urine
             sample for pregnancy testing that must be negative one week before being allowed to
             participate in the study.

          6. Subjects must be planning to remain in the study area during the trial.

          7. Subjects and/or their parents must be trained on the proper use of the Epi-Pen to be
             allowed to enroll in the study.

        Exclusion Criteria:

        Due to the risk of serious systemic anaphylactic reactions to peanut in this study, we will
        exclude:

          1. Patients with acute infections, autoimmune disease, severe cardiac disease, and those
             who are treated with beta-adrenergic antagonistic drugs (beta-blockers, which increase
             the risk of more serious symptoms of anaphylaxis).

          2. Subjects having a history of severe anaphylaxis to peanut requiring intubation or
             admission to an ICU, frequent urticaria, or history consistent with poorly controlled
             persistent asthma.

          3. Total IgE &gt; 2,000 IU/mL.

          4. Subjects with unstable angina, significant arrhythmia, uncontrolled hypertension,
             chronic sinusitis, or other chronic or immunological diseases that in the mind of the
             investigator might interfere with the evaluation or administration of the test drug or
             pose additional risk to the subject e.g. gastrointestinal or gastroesophageal disease,
             chronic infections, scleroderma, hepatic and gallbladder disease, chronic non-allergic
             pulmonary disease.

          5. Subject with an FEV1 or PEF less than 80% predicted with or without controller
             medication (if able to perform the maneuver) at screening, the oral desensitization
             visit, or food challenge visit.

          6. Subjects who have received an experimental drug in the last 30 days prior to admission
             into this study or who plan to use an experimental drug during the study, who are
             current users of oral, intramuscular, or intravenous corticosteroids, or tricyclic
             antidepressants, or who are using medication that could induce adverse
             gastrointestinal reactions during the study.

          7. Subjects refusing to sign the EpiPen Training Form.

          8. Pregnant or breast-feeding females.

          9. Subjects with severe food associated eczema, dermatitis herpetiformis, eosinophilic
             esophagitis, eosinophilic enteritis, proctocolitis, food protein induced enterocolitis
             syndrome (FPIES) or other gastrointestinal diseases. These requirements are necessary
             to limit the study to patients with primarily IgE mediated peanut allergy, and to
             exclude patients with peanut sensitivity mediated by cellular/T cell (non-IgE
             mediated) mechanisms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rima T Rachid, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital, Harvard Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lynda Schneider, MD</last_name>
    <role>Study Director</role>
    <affiliation>Children's Hospital, Harvard Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Boston, Harvard Medical School</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2011</study_first_submitted>
  <study_first_submitted_qc>February 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2011</study_first_posted>
  <results_first_submitted>February 4, 2015</results_first_submitted>
  <results_first_submitted_qc>February 4, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 20, 2015</results_first_posted>
  <last_update_submitted>March 18, 2015</last_update_submitted>
  <last_update_submitted_qc>March 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children’s Hospital</investigator_affiliation>
    <investigator_full_name>Lynda Schneider</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>peanut allergy</keyword>
  <keyword>Xolair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Omalizumab, Oral Desensitization</title>
          <description>Omalizumab treatment and oral peanut desensitization</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omalizumab, Oral Desensitization</title>
          <description>Omalizumab treatment and oral peanut desensitization</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 500 mg Peanut Flour (Cumulative Dose, 1,000 mg)</title>
        <description>To tolerate refers to the ability of the patient to ingest the challenge dose of 500 mg peanut flour (1000 mg cumulatively) with either no or mild symptoms.</description>
        <time_frame>First day of desensitization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab, Oral Desensitization</title>
            <description>Omalizumab treatment and oral peanut desensitization</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 500 mg Peanut Flour (Cumulative Dose, 1,000 mg)</title>
          <description>To tolerate refers to the ability of the patient to ingest the challenge dose of 500 mg peanut flour (1000 mg cumulatively) with either no or mild symptoms.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 4,000 mg of Peanut Flour.</title>
        <description>To tolerate refers to the ability of the patient to ingest the final challenge of 4000mg peanut flour, with either no or mild symptoms.</description>
        <time_frame>after 7-8 wks of desensitization</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omalizumab, Oral Desensitization</title>
            <description>Omalizumab treatment and oral peanut desensitization</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Tolerated Rapid Oral Peanut Desensitization to a Dose of 4,000 mg of Peanut Flour.</title>
          <description>To tolerate refers to the ability of the patient to ingest the final challenge of 4000mg peanut flour, with either no or mild symptoms.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Omalizumab, Oral Desensitization</title>
          <description>Omalizumab treatment and oral peanut desensitization</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <description>Allergic reaction to peanut. 6 of the 13 subjects (46%) had no or a single grade 1 allergic reaction. Six of the 13 patients (39%) experienced a grade 2 or 3 adverse event</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Coordinator</name_or_title>
      <organization>Boston Children's Hospital</organization>
      <phone>6173556127</phone>
      <email>sara.little@childrens.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

